ID
45673
Descripción
Principal Investigator: Kwok-wai Lo, Chinese University of Hong Kong, Hong Kong, China MeSH: Nasopharyngeal Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001244 Nasopharyngeal carcinoma (NPC) is an aggressive head and neck cancer characterized by Epstein-Barr virus (EBV) infection and dense lymphocyte infiltration. The scarcity of NPC genomic data hinders the understanding of NPC biology, disease progression, and rational therapy design. Here, we performed whole-exome sequencing (WES) on 111 micro-dissected EBV-positive NPCs, with 15 cases subjected to further whole-genome sequencing (WGS), to determine its mutational landscape. We identified enrichment for genomic aberrations of multiple negative regulators of the NF-kB pathway in a total of 41% of cases including CYLD, TRAF3, NFKBIA and NLRC5. Functional analysis confirmed novel inactivating CYLD mutations as drivers for NPC cell growth. The EBV oncoprotein latent member protein 1 (LMP1) functions to constitutively activate NF-kB signaling, and we observed mutual exclusivity among somatic NF-kB pathway aberrations and LMP1-overexpression, suggesting that NF-kB activation is selected for by both somatic and viral events during NPC pathogenesis.
Link
Palabras clave
Versiones (1)
- 6/4/23 6/4/23 - Simon Heim
Titular de derechos de autor
Kwok-wai Lo, Chinese University of Hong Kong, Hong Kong, China
Subido en
6 de abril de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs001244 Nasopharynx Cancer Whole Exome Sequencing
Subject ID, sample ID, and sample use variable of participants with nasopharynx cancer and involved in the "Nasopharynx Cancer Whole Exome Sequencing" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with nasopharynx cancer and involved in the "Nasopharynx Cancer Whole Exome Sequencing" project.
- Subject ID, sample ID, analyte type, sample type, and tumor type of participants with nasopharynx cancer and involved in the "Nasopharynx Cancer Whole Exome Sequencing" project.
- Subject ID, age, gender, family history of nasopharynx cancer, life status, time when participant was alive, stage of primary tumor, stage of metastasis, stage of lymph nodes, participants survive without signs or symptoms of disease, treatment, smoking, and alcohol consumption of participants with nasopharynx cancer and involved in the "Nasopharynx Cancer Whole Exome Sequencing" project.
- Subject ID, sample ID, and sample use variable of participants with nasopharynx cancer and involved in the "Nasopharynx Cancer Whole Exome Sequencing" project.
Similar models
Subject ID, sample ID, and sample use variable of participants with nasopharynx cancer and involved in the "Nasopharynx Cancer Whole Exome Sequencing" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with nasopharynx cancer and involved in the "Nasopharynx Cancer Whole Exome Sequencing" project.
- Subject ID, sample ID, analyte type, sample type, and tumor type of participants with nasopharynx cancer and involved in the "Nasopharynx Cancer Whole Exome Sequencing" project.
- Subject ID, age, gender, family history of nasopharynx cancer, life status, time when participant was alive, stage of primary tumor, stage of metastasis, stage of lymph nodes, participants survive without signs or symptoms of disease, treatment, smoking, and alcohol consumption of participants with nasopharynx cancer and involved in the "Nasopharynx Cancer Whole Exome Sequencing" project.
- Subject ID, sample ID, and sample use variable of participants with nasopharynx cancer and involved in the "Nasopharynx Cancer Whole Exome Sequencing" project.
C1299222 (UMLS CUI [1,2])
C2939420 (UMLS CUI [1,2])
C0521158 (UMLS CUI [1,3])
C1515974 (UMLS CUI [1,4])
C1518422 (UMLS CUI [1,5])
C0027442 (UMLS CUI [1,6])
C0494165 (UMLS CUI [1,7])
C0345746 (UMLS CUI [1,8])
C0153676 (UMLS CUI [1,9])
C2103490 (UMLS CUI [1,10])
C0686619 (UMLS CUI [1,11])
C0012854 (UMLS CUI [1,2])